

UC Davis

Dermatology Online Journal

Title

Eccrine poromatosis following chemotherapy and radiation therapy

Permalink

<https://escholarship.org/uc/item/9177r4fp>

Journal

Dermatology Online Journal, 25(11)

Authors

Nguyen, Khoa
Kim, Gene
Chiu, Melvin

Publication Date

2019

DOI

10.5070/D32511046146

Copyright Information

Copyright 2019 by the author(s). This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Peer reviewed

Eccrine poromatosis following chemotherapy and radiation therapy

Khoa Nguyen¹ BS, Gene Kim² MD, Melvin Chiu² MD MPH

Affiliations: ¹University of Central Florida College of Medicine, Orlando, Florida, USA, ²Department of Dermatology, University of Southern California Keck School of Medicine, Los Angeles, California, USA

Corresponding Author: Melvin Chiu MD, MPH, University of Southern California, 1450 San Pablo Street, Los Angeles, CA 90033, Tel: 323-442-6206; Fax: 323-442-6299, Email: Melvin.chiu@med.usc.edu

Abstract

Eccrine poroma presents as a single, symptomless erythematous papule in areas with a high density of eccrine sweat glands. Although rare, eccrine poromas can present as multiple lesions, otherwise known as eccrine poromatosis. The etiology of eccrine poromatosis is unclear. We present two cases of eccrine poromatosis in patients who had undergone chemotherapy, radiation therapy, and stem cell transplant. This case report serves to raise awareness of this condition and highlight its association with malignancies and their treatment.

Keywords: eccrine poromatosis, eccrine poroma, poroma, chemotherapy, radiation therapy, malignancies

Introduction

Eccrine poromas are benign, adnexal, slow-growing neoplasms originating from the intra-epidermal eccrine duct and the acrosyringium. These tumors belong to a group of benign eccrine ductal tumors that also include hidroacanthoma simplex, dermal ductal tumor, and poroid hidradenoma. Eccrine poromas account for nearly 65% of poroid neoplasms and 10% of sweat gland

tumors [1]. No predilection for race or sex have been identified.

Clinically, an eccrine poroma presents as a single, symptomless erythematous papule in areas with a high density of eccrine sweat glands such as the palms, soles, and fingers. Although rare, eccrine poromas can present as multiple lesions, otherwise known as eccrine poromatosis. A broader distribution that includes the neck, trunk, and face may be observed. Newer reports suggest that eccrine poromatosis may occur in the setting of concurrent or history of chemotherapy, but the relationship is unclear [2].

We present two cases of eccrine poromatosis in patients who had undergone chemotherapy, radiation therapy, and stem cell transplant for lymphoma.

Case Synopsis

Case 1

A 58-year-old man presented to the clinic with four pink, pedunculated, exophytic, 2-14mm sized papules on his dorsal left foot, right flank, and left groin (**Figure 1**). The patient's medical history included diffuse large B-cell lymphoma with several masses including one lesion near the hippocampus. He had extensive treatment 10




Figure 1. Eccrine poromas of the **A, B)** dorsal left foot and **C, D)** right flank.




Figure 2. Eccrine poroma histopathologic findings of interanastomosing islands of cuboidal cells with occasional ductal differentiation. H&E, **A)** 40 \times and **B)** 200 \times .




Figure 3. Eccrine poromas on the right upper back (left) and right anterior shoulder (right).

years prior that included 5 rounds of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); 20 rounds of radiation; intrathecal liposomal cytarabine; stem cell transplant; and 8 rounds of methotrexate, etoposide, and cyclophosphamide. Outside of his history of lymphoma, the patient's past medical history was unremarkable. Review of systems was also unremarkable. Four shave biopsies were performed. Histopathological examination demonstrated an epidermis with inter-anastomosing islands of monotonous appearing bland cuboidal cells with occasional ductal differentiation (**Figure 2**). Similar epithelial islands

were also seen in the dermis. These findings were consistent with eccrine poromatosis. No further treatment was performed. The patient was then lost to follow up.

Case 2

A 72-year-old man presented to the clinic with a pink eroded papule on the right anterior shoulder and a pink and yellow papule on the right upper back (**Figure 3**). The patient's medical history included mantle cell lymphoma 10 years prior for which he received high-dose R-CHOP, stem cell transplant; he remained on maintenance rituximab and lenalidomide. He also had a history of prostate cancer 6 years prior for which he underwent radical prostatectomy and radiotherapy. The patient denied any symptoms or trauma to the affected areas. Shave excisions of the two papules were performed. Histopathological examination demonstrated an epidermis with superficial islands of monotonous-appearing cuboidal cells with epidermal interconnection and prominent ductal differentiation (**Figure 4**). These findings were consistent with eccrine poromatosis. No further treatment was performed. Four years later, there is no evidence of recurrence to date.




Figure 4. Eccrine poroma histopathologic findings of an epidermis with superficial islands of monotonous appearing cuboidal cells with epidermal interconnection and prominent ductal differentiation. H&E, **A**) 40× and **B**) 100×.

Case Discussion

Multiple eccrine poromas are an uncommon presentation of a rare disease. This case report serves to raise awareness of this condition and highlight its association with malignancies and their treatment.

Although no definitive etiology for eccrine poromatosis has yet been described, possible etiologies for the development of multiple eccrine poromas include chemotherapy, radiation, actinic damage, and human papillomavirus [3]. Indeed, in both of our patients, the identified potential etiologies among those previously reported were a history of high-dose chemotherapy and radiation therapy 10 years prior to eccrine poromatosis appearance. A recent case of eruptive poromatosis in a pregnant woman in her third trimester indicates that there could be a hormonal association [4]. Others have suspected a tumor suppressor gene defect in eccrine cells [5].

Chemotherapy or radiation therapy may be the most likely etiology for eccrine poromatosis. That is, a history of chemotherapy and/or radiation therapy is often noted in eccrine poromatosis cases ([Table 1](#)), [2, 3, 5-17]. Although it is common for patients to receive both chemotherapy and radiation therapy throughout the course of their neoplastic treatment, eccrine poromatosis most commonly occurs on non-irradiated skin in patients who received polychemotherapy [2]. Additionally, eccrine poromatosis developed in patients who received chemotherapy without radiation therapy as well. Specifically, Yoshii et al. described a case of eccrine poromatosis in a patient with systemic lupus erythematosus who received

cyclophosphamide and mizoribine but no radiation therapy [18].

Chemotherapy is also implicated in the development of other eccrine conditions including neutrophilic eccrine hidradenitis and syringosquamous metaplasia. Previous reports suggested that the chemotherapeutic metabolites accumulate in the sweat apparatus and are either directly cytotoxic to, or induce remodeling in, the eccrine sweat glands [2, 19]. Because eccrine poromatosis occurs years, sometimes even decades, following chemotherapy exposure, it is likely that there is a combination of remodeling and regeneration that triggers tumor development [8].

Treatment of eccrine poromas is typically done by simple excision. Other successful treatment modalities have included electrosurgical desiccation, cryotherapy, and imiquimod [4, 9]. Eccrine poromas can rarely transform into eccrine porocarcinomas. Therefore, careful monitoring or treatment by a dermatologist is recommended.

Conclusion

Eccrine poromatosis is a condition characterized by an eruption of multiple eccrine poromas. Various etiologies have been discussed in the literature. We present two cases of eccrine poromatosis in patients who had undergone chemotherapy, radiation therapy, and stem cell transplant. This case report raises awareness of this condition and highlights its association with malignancies and their treatment.

Potential conflicts of interest

The authors declare no conflicts of interests.

References

1. Chen CC, Chang YT, Liu HN. Clinical and histological characteristics of poroid neoplasms: a study of 25 cases in Taiwan. *Int J Dermatol*. 2006;45:722-7. [PMID: 16796636].
2. Fujii K, Aochi S, Takeshima C, et al. Eccrine poromatosis associated with polychemotherapy. *Acta Derm Venereol*. 2012;92:687-90. [PMID: 22294042].
3. Deckelbaum S, Touloei K, Shitabata PK, Sire DJ, Horowitz D. Eccrine poromatosis: case report and review of the literature. *Int J Dermatol*. 2014;53:543-8. [PMID: 23968240].
4. North JP, Lo J, Landers M. Poromatosis in pregnancy: a case of 8 eruptive poromas in the third trimester. *Cutis*. 2012;89:81-3. [PMID: 22474731].
5. Mahlberg MJ, McGinnis KS, Draft KS, Fakhrazadeh SS. Multiple eccrine poromas in the setting of total body irradiation and immunosuppression. *J Am Acad Dermatol*. 2006;55(2 Suppl):S46-9. [PMID: 16843124].
6. Navi D, Fung M, Lynch PJ. Poromatosis: the occurrence of multiple eccrine poromas. *Dermatol Online J*. 2008;14:3. [PMID: 18319020].
7. Diamantis ML, Richmond HM, Rady PL, et al. Detection of human papillomavirus in multiple eccrine poromas in a patient with chronic graft-vs-host disease and immunosuppression. *Arch Dermatol*. 2011;147:120-2. [PMID: 21242407].
8. Valdebran MA, Hong C, Cha J. Multiple Eruptive Eccrine Poromas Associated with Chemotherapy and Autologous Bone Marrow Transplantation. *Indian Dermatol Online J*. 2018;9:259-61. [PMID: 30050816].
9. Mayo TT, Kole L, Elewski B. Eccrine Poromatosis: Case Report, Review of the Literature, and Treatment. *Skin Appendage Disord*. 2015;1:95-8. [PMID: 27170941].
10. Kurokawa M, Amano M, Miyaguni H, Tateyama S, Ogata K, Idemori M, Setoyama M. Eccrine poromas in a patient with mycosis fungoides treated with electron beam therapy. *Br J Dermatol*. 2001;145:830-3. [PMID: 11736912].
11. Miura T, Yamamoto T. Eruptive poromatosis following radiotherapy. *Am J Dermatopathol*. 2013;35:615-7. [PMID: 23676317].
12. Nguyen BT, Lortscher DN, Lee RA. Multiple poromas in a bone marrow transplant recipient: A case report. *Dermatol Online J*. 2012;18:9. [PMID: 22863631].
13. Garshick M, DeFilippis EM, Harp J, Gaan J. Eccrine poromatosis in a patient with acute myeloid leukemia following chemotherapy. *Dermatol Online J*. 2014;20(11). [PMID: 25419754].
14. Takahashi C, Nishi K, Minami-Hori M, et al. Multiple poromas following combination chemotherapy and autologous peripheral blood stem cell transplantation. *J Dermatol*. 2015;42:430-2. [PMID: 25676313].
15. Sherman V, Reed J, Hollowood K, Littlewood T, Burge SM. Poromas and porokeratosis in a patient treated for solid-organ and haematological malignancies. *Clin Exp Dermatol*. 2010;35:e130-2. [PMID: 19958368].
16. Lim TM, Weir J, Fearfield L. Eruptive poromatosis in a patient with breast cancer. *J Cutan Pathol*. 2018. [PMID: 29797732].
17. Aung PP, Rady PL, Nagarajan P, et al. Detection of Merkel Cell Polyoma Virus and Beta Human Papillomavirus in Multiple Eccrine Poromas in a Patient With Acute Leukemia Treated With Stem Cell Transplant. *Am J Dermatopathol*. 2017;39:489-91. [PMID: 27655121].
18. Yoshii Y, Matsuo S, Nishizawa A, Satoh T. Multiple eccrine poromas in a patient with systemic lupus erythematosus. *Eur J Dermatol*. 2018;28:837. [PMID: 30325314].
19. Yeh I, George E, Fleckman P. Eccrine hidradenitis sine neutrophils: a toxic response to chemotherapy. *J Cutan Pathol*. 2011;38:905-10. [PMID: 21955315].

Table 1. Malignancy-associated eccrine poromatosis.

Reference	Age; Sex	Race	Location	Size (mm)	No. of poromas	Cancer	Treatment of cancer	Treatment of poromas	Follow up; recurrence?
Fujii et al. (2012), [2]	66; F	J	Bilateral thighs, left forearm, hip, and lower abdomen	1-7mm	>19	1. Chronic lymphocytic leukemia 2. Follicular B-cell lymphoma (left parotid gland, mediastinum, and para-aortic lymph nodes)	1. Cyclophosphamide and "other chemotherapeutic regimens" 2. Epirubicin, vincristine, mitoxantrone, cyclophosphamide, methotrexate, prednisolone, etoposide, cisplatin, and "unidentified regimens" 3. Surgical resection and radiation therapy to right eyelid	N/A	N/A
Fujii et al. (2012), [2]	62; M	N/A	Left lower leg, right heel, and right sole	4-7mm	3	Malignant fibrous histiocytoma (right thigh)	Wide resection of right thigh, doxorubicin, ifosfamide. and radiation therapy to right leg	Excisional biopsy	N/A
Fujii et al. (2012), [2]	59; M	J	Right palm, left hand, and sole and heel of left foot	3-15mm	4	Malignant B-cell lymphoma	CHOP, methotrexate, and rituximab	Biopsy and resection	N/A
Fujii et al. (2012), [2]	72; M	J	Back, right thigh, right knee, trunk, and extremities	2-15mm	>5	Diffuse large B-cell lymphoma	CHOP and etoposide	Excisional biopsy	N/A
Deckelbaum et al. (2014), [3]	73; M	N/A	Soles	N/A	30	Testicular lymphoma	CHOP and radiation	Excisional biopsy	N/A
Mahlberg et al. (2006), [5]	42; M	N/A	Distal extremities, primarily palms and left sole	4-16mm	14	Acute lymphocytic leukemia	Chemotherapy, total body irradiation, and allogenic bone marrow transplant.	Shave biopsy	N/A
Navi et al. (2008), [6]	64; M	N/A	Chest, left nipple, eyelid, left forearm, and left ankle	N/A	7	Non-Hodgkin lymphoma with history of colorectal carcinoma	CHOP and rituximab	Shave biopsy and complete excision	N/A

Diamantis et al. (2011), [7]	53; M	N/A	Palms, left elbow, and heels	2-6mm	6	Mantle cell lymphoma	Allogenic stem cell transplant. Photopheresis, tacrolimus, systemic corticosteroids, and mycophenolate mofetil for chronic graft-versus-host disease	Shave biopsy	N/A
Valdebran et al. (2018), [8]	32; F	N/A	Feet and lower eyelid	1-2mm	17	Acute promyelocytic leukemia	Tretinoin, amphotericin B, busulfan, etoposide, arsenic trioxide, cytarabine, and bone marrow stem cell transplant	Mild electrocauterization	N/A
Mayo et al. (2015), [9]	43; M	AA	Bilateral plantar feet, hands, and arms	1-9mm	16	Mantle cell lymphoma	Cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, and autologous stem cell transplant (pre-transplant regimen of busulfan, cyclophosphamide, and etoposide)	Excision to four eccrine poromas, imiquimod 5% cream and cryosurgery ablation	N/A
Kurokawa et al. (2001), [10]	72; M	N/A	Bilateral thighs, right lumbus, left elbow, left brachium, left leg, bilateral shoulders, left buttock, left inguinal region, and left breast	3-8mm	14	Mycosis fungoides	Whole body electron beam irradiation (except for the head), regional electron beam irradiation (bilateral lower extremities, right antebrachium, left palm, left antebrachium, trunk, and buttocks), and interferon- γ 1a	Shave biopsy and observation	>2 years with no changes
Miura et al. (2013), [11]	72; F	N/A	Abdomen, trunk, neck, and extremities	5mm	11	Nasolacrimal duct adenocarcinoma	Radical excision and post-operative radiation therapy	Surgical removal under anesthesia	N/A
Nguyen et al. (2012), [12]	25; M	N/A	Right dorsal foot, right medial foot, both soles,	N/A	8	Acute myelogenous leukemia	Autologous bone marrow transplant	Salicylic acid (did not respond) and	N/A

			and both heels					shave biopsy	
Garshick et al. (2014), [13]	46; M	N/A	Palms and soles	2-5mm	22	Acute myeloid leukemia	Cytarabine, daunorubicin, etoposide, and autologous stem cell transplant	Shave excision	N/A
Takahashi et al. (2015), [14]	63; F	N/A	Right thigh, lower abdomen, left forearm, and bilateral calves	1-12mm	≥5	Acute myelocytic leukemia	Idarubicin, cytarabine, prednisolone, and autologous peripheral blood stem cell transplant	Excision	N/A
Sherman et al. (2010), [15]	32; M	N/A	Left great toe, right 5 th toe, left sole, and webspace between left 4 th and 5 th toe	2-8mm	4	1. Testicular teratoma with para-aortic and supraclavicular lymph node involvement and pulmonary metastasis 2. Acute myeloid leukemia 3. Squamous cell carcinoma of esophagus	1. Orchiectomy, bleomycin, cisplatin, and etoposide 2. Cytarabine, daunorubicin, etoposide, allogenic bone marrow transplant (preceded by cyclophosphamide and total body irradiation), and fludarabine. Second allogenic bone marrow transplant (melphalan and fludarabine). 3. Ivor-Lewis esophagectomy 4. Prednisolone and cyclosporine (for graft-versus-host disease)	Curettage and shave excision	>8 years no recurrence
Lim et al. (2018), [16]	63; F	N/A	Left thigh, left buttock, left breast, left clavicular region, left hand and fingers, left forearm, left lateral neck, right arm, right temple, and scalp	N/A	> 18	Metastatic right breast cancer	Mastectomy, 5-fluorouracil, epirubicin, cyclophosphamide, letrozole, paclitaxel, trastuzumab, pertuzumab, tamoxifen, resection of right infraclavicular mass, and radiation therapy to right chest wall, axilla, and supraclavicular fossa	Shave excision	N/A

Aung et al. (2017), [17]	45; M	N/A	Toes, heels, and fingers	3-6mm	>3	Acute myeloid leukemia	Chemotherapy and allogenic stem cell transplant	Biopsy	N/A
--------------------------	-------	-----	--------------------------	-------	----	------------------------	---	--------	-----

AA= African American; CHOP= Cyclophosphamide, doxorubicin, vincristine, and prednisolone; J= Japanese; mm= millimeter; No.= Number of poromas; Ref.=Reference, Tx= Treatment.